Lupus Nephritis and JAK Inhibitors: Updates and Insights

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope
Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein 
axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros
Can We Make Clinical Trials Better?:Dr. Janet Pope
Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey 
IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui
IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed 
Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes
So really, are JAKs Safe?:Dr. Janet Pope
Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey,  Louise Pollard and Bharat Kumar
The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes 
The Real Value of JAKi is Beyond RA:Dr. David Liew 
Vaccine Responses:The DMARD Counts:Dr. David Liew